Oric Pharmaceuticals Inc (ORIC)
$13.24
$-0.50
(-3.64%)
As on 28-Aug-2026 16:00EDT
Market cap
$1,372 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$3.7
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
103,652,656
7 Years Aggregate
CFO
$-330.92 Mln
EBITDA
$-343.00 Mln
Net Profit
$-413.97 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oric Pharmaceuticals Inc (ORIC)
| 61.9 | 10.1 | 54.3 | 29.0 | 13.4 | -10.1 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Oric Pharmaceuticals Inc (ORIC)
| 1.4 | -12.2 | 56.2 | -59.9 | -56.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oric Pharmaceuticals Inc (ORIC)
|
13.2 | 1,372.4 | 0.0 | -140.4 | -- | -36.7 | -- | 3.7 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Oric Pharmaceuticals Inc (ORIC)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include... enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read more
-
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Richard A. Heyman Ph.D.
-
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Dr. Richard A. Heyman Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Oric Pharmaceuticals Inc (ORIC)
What is the current share price of Oric Pharmaceuticals Inc (ORIC) Today?
The share price of Oric Pharmaceuticals Inc (ORIC) is $13.24 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Oric Pharmaceuticals Inc (ORIC) has given a return of 13.36% in the last 3 years.
What is the current PB & PE ratio of Oric Pharmaceuticals Inc (ORIC)?
Since, TTM earnings of Oric Pharmaceuticals Inc (ORIC) is negative, P/E ratio is not available.
The P/B ratio of Oric Pharmaceuticals Inc (ORIC) is 3.74 times as on 28-Aug-2026, a 30 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.55 |
1.87 |
2024 |
-4.46 |
2.35 |
2023 |
-5.25 |
2.36 |
2022 |
-2.65 |
1.06 |
2021 |
-7.45 |
2.12 |
What is the 52 Week High and Low of Oric Pharmaceuticals Inc (ORIC)?
The 52-week high and low of Oric Pharmaceuticals Inc (ORIC) are Rs 14.93 and Rs 7.23 as of 30-Aug-2026.
What is the market cap of Oric Pharmaceuticals Inc (ORIC)?
Oric Pharmaceuticals Inc (ORIC) has a market capitalisation of $ 1,372 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Oric Pharmaceuticals Inc (ORIC)?
Before investing in Oric Pharmaceuticals Inc (ORIC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.